Paper38102001
Harnessing the potential of CD40 agonism in cancer therapy.
Zhou Y and 2 others. Cytokine Growth Factor Rev, 2024. Cited by 51 papers, by iCite.
Cite this record
ConductScience Library. Harnessing the potential of CD40 agonism in cancer therapy. Papers, record 38102001. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38102001
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Review, Research Support, U.S. Gov't, Non-P.H.S., Research Support, N.I.H., Extramural
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| CD40 Antigens | Major topic |
| Neoplasms | Major topic |
| Humans | |
| CD40 Ligand | |
| T-Lymphocytes | |
| Cytokines |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| I01 BX002301 | BLRD VA | United States | I01BX002301 | PubMed and NIH | NIH RePORTER |
| IK6 BX005225 | BLRD VA | United States | IK6BX005225 | PubMed and NIH | NIH RePORTER |
| R01 CA116021 | NCI NIH HHS | United States | R01CA116021 | PubMed and NIH | NIH RePORTER |
| R01 CA243326 | NCI NIH HHS | United States | R01CA243326 | PubMed and NIH | NIH RePORTER |
References145
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 7539000 | Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis. | J Biol Chem | 1995 | https://conductscience.org/library/papers/7539000 | PubMed |
| 2 | 7730613 | Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. | J Immunol | 1995 | https://conductscience.org/library/papers/7730613 | PubMed |
| 3 | 7595225 | CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. | J Exp Med | 1995 | https://conductscience.org/library/papers/7595225 | PubMed |
| 4 | 19118532 | Mechanisms of LPS-induced CD40 expression in human peripheral blood monocytic cells. | Biochem Biophys Res Commun | 2009 | https://conductscience.org/library/papers/19118532 | PubMed |
| 5 | 15209378 | PI3K signaling controls cell fate at many points in B lymphocyte development and activation. | Semin Cell Dev Biol | 2004 | https://conductscience.org/library/papers/15209378 | PubMed |
| 6 | 35292514 | The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation. | J Immunother Cancer | 2022 | https://conductscience.org/library/papers/35292514 | PubMed |
| 7 | 34092233 | Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade. | Mol Cancer | 2021 | https://conductscience.org/library/papers/34092233 | PubMed |
| 8 | 8626375 | Human native soluble CD40L is a biologically active trimer, processed inside microsomes. | J Biol Chem | 1996 | https://conductscience.org/library/papers/8626375 | PubMed |
| 9 | 10096561 | Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. | Cancer Res | 1999 | https://conductscience.org/library/papers/10096561 | PubMed |
| 10 | 32583318 | Beyond Antibodies: The DARPin® Drug Platform. | BioDrugs | 2020 | https://conductscience.org/library/papers/32583318 | PubMed |
| 11 | 37509357 | Generation of Orthotopic Patient-Derived Xenografts in Humanized Mice for Evaluation of Emerging Targeted Therapies and Immunotherapy Combinations for Melanoma. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37509357 | PubMed |
| 12 | 22421945 | Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo. | J Immunother | 2012 | https://conductscience.org/library/papers/22421945 | PubMed |
| 13 | 24189063 | CD154 is released from T-cells by a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) and ADAM17 in a CD40 protein-dependent manner. | J Biol Chem | 2013 | https://conductscience.org/library/papers/24189063 | PubMed |
| 14 | 11825564 | A CD40 Signalosome anchored in lipid rafts leads to constitutive activation of NF-kappaB and autonomous cell growth in B cell lymphomas. | Immunity | 2002 | https://conductscience.org/library/papers/11825564 | PubMed |
| 15 | 18548529 | Up-regulation of CD40 with juxtacrine activity in human nonsmall lung cancer cells correlates with poor prognosis. | Cancer | 2008 | https://conductscience.org/library/papers/18548529 | PubMed |
| 16 | 31555278 | TRIM21-From Intracellular Immunity to Therapy. | Front Immunol | 2019 | https://conductscience.org/library/papers/31555278 | PubMed |
| 17 | 7514045 | Inhibition of human B-cell lymphoma growth by CD40 stimulation. | Blood | 1994 | https://conductscience.org/library/papers/7514045 | PubMed |
| 18 | 37270599 | CXCR2 expression during melanoma tumorigenesis controls transcriptional programs that facilitate tumor growth. | Mol Cancer | 2023 | https://conductscience.org/library/papers/37270599 | PubMed |
| 19 | 35190724 | Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting. | Nat Cancer | 2022 | https://conductscience.org/library/papers/35190724 | PubMed |
| 20 | 15879094 | CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. | J Immunol | 2005 | https://conductscience.org/library/papers/15879094 | PubMed |
Cited by38
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 51 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42706236 | B cells in cancer: functions, mechanisms and therapeutic advances. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42706236 | PubMed |
| 42630934 | B-cells in breast cancer: current insights and challenges. | Front Oncol | 2026 | https://conductscience.org/library/papers/42630934 | PubMed |
| 42548768 | Innate Immune Cells in Non-Small Cell Lung Cancer: Roles in Tumor Progression and Therapeutic Responses. | Cancer Innov | 2026 | https://conductscience.org/library/papers/42548768 | PubMed |
| 42499227 | CD40 Agonist Therapy in Melanoma: Translating Preclinical Promise Into Clinical Practice. | Pigment Cell Melanoma Res | 2026 | https://conductscience.org/library/papers/42499227 | PubMed |
| 42498930 | Agonistic bispecific antibodies: an emerging frontier in antibody therapeutics. | J Transl Med | 2026 | https://conductscience.org/library/papers/42498930 | PubMed |
| 42370186 | TAM-targeted nanomedicine in cancer: biological basis, therapeutic strategies, and translational perspectives. | Theranostics | 2026 | https://conductscience.org/library/papers/42370186 | PubMed |
| 42353028 | CD40LG/CD28-Mediated Rho GTPase Signaling Drives Survival and Chemoresistance in Non-ETP T-ALL. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42353028 | PubMed |
| 42292487 | The CD40-CD154 axis in transplantation: from immunobiology to therapeutic targeting. | Front Immunol | 2026 | https://conductscience.org/library/papers/42292487 | PubMed |
| 42279326 | CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic Targeting. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42279326 | PubMed |
| 42233099 | Targeting tumor-associated macrophages in pancreatic cancer. | ILIVER | 2026 | https://conductscience.org/library/papers/42233099 | PubMed |
| 42218726 | Current advances in immunotherapy for KRAS-Mutant pancreatic cancer. | Clin Exp Med | 2026 | https://conductscience.org/library/papers/42218726 | PubMed |
| 42164656 | Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42164656 | PubMed |
| 42121263 | Metabolic pattern changes of macrophages during cancer development and progression. | J Transl Med | 2026 | https://conductscience.org/library/papers/42121263 | PubMed |
| 42067655 | Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study. | Nat Cancer | 2026 | https://conductscience.org/library/papers/42067655 | PubMed |
| 42001092 | Actomyosin rings constrain CD40 mobility to organize the dendritic cell immunological synapse. | Cell Commun Signal | 2026 | https://conductscience.org/library/papers/42001092 | PubMed |
| 41988365 | T‑Cell Immunoreceptor with Ig and Immunoreceptor Tyrosine-Based Inhibitory Motif Domains/Cluster of Differentiation 40 Cellular Nanovesicles Carrying Oxaliplatin Exhibited Superior Pancreatic Cancer Cells Therapy. | ACS Pharmacol Transl Sci | 2026 | https://conductscience.org/library/papers/41988365 | PubMed |
| 41609852 | Pharmacovigilance study and genetic target prediction analysis of FDA adverse event reporting system for anticancer drug-associated interstitial lung disease. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/41609852 | PubMed |
| 41526341 | RAS/MEK/PI3K pathway inhibition augments response to CD40 agonism by targeting CD11b+ Bregs thereby overcoming melanoma PD1-resistance. | Nat Commun | 2026 | https://conductscience.org/library/papers/41526341 | PubMed |
| 41375696 | The Effect of T Regulatory Cell Infiltration on Survival Outcomes in Metastatic Pancreatic Cancer Patients with a Review of Immunobiology, Prognostic Value and Future Therapeutic Options. | J Clin Med | 2025 | https://conductscience.org/library/papers/41375696 | PubMed |
| 41335396 | Decoding the role of mesothelin in tumor dynamics and targeted treatment innovations. | Mol Biomed | 2025 | https://conductscience.org/library/papers/41335396 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD40 | 958 | PubTator's text mining | https://conductscience.org/library/genes/958 | NCBI Gene |
| CD40LG | 959 | PubTator's text mining | https://conductscience.org/library/genes/959 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38102001
GET https://conductscience.org/api/papers/v1/38102001/references?page=2